Lentiviruses as vectors for CNS diseases

Current Topics in Microbiology and Immunology

Volumn 261, Issue , 2002, Pages 191-209

  Deglon N ^a   Aebischer, P ^a  

^a University of Lausanne Medical Center   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR;

CENTRAL NERVOUS SYSTEM DISEASE; GENE EXPRESSION; HUNTINGTON CHOREA; IMMUNE RESPONSE; INFLAMMATION; LENTIVIRINAE; LYSOSOME STORAGE DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETINA DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENE;

LENTIVIRUS;

EID: 0036210124     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-56114-6_10     Document Type: Review

References (80)

1. A mutant mouse menagerie
2. Transgenic and knockout mice in the study of neurodegenerative diseases
3. Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons
4. Human gene therapy
5. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
6. Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioural improvements in a 6-OHDA model of Parkinson's disease using GDNF
7. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency
8. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
9. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
10. Bcl-xL protects adult septal cholinergic neurons from axotomized cell death
11. Parkinson's disease: A neurodegenerative disease particularly anemable to gene therapy
12. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer
13. Interactions of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells
14. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system
15. Efficient gene transfer and expression of biologically active glial cell line-derived neurotrophic factor in rat motoneurons transduced wit lentiviral vectors
16. In vivo gene therapy of metachromatic leukodystrophy by lenetiviral vectors: Correction of neuropathology and protection against learning impairments in affected mice
17. Lentiviral-mediated delivery of mutated huntingtin fragments as a new strategy to develop animal models of Huntington's disease
18. Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease
19. A third-generation lentivirus vector with a conditional packaging system
20. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences
21. Cotransduction of nondividing cells using lentiviral vectors
22. Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials
23. vit mouse using a lentiviral vector
24. Functional recovery in parkinsonian monkeys treated with GDNF
25. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
26. Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector
27. Phenotype of arylsulfatase A-deficient mice: Relationship to human metachromatic leukodystrophy
28. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
29. Glial cell-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo
30. Species-specific, postentry barriers to primate immunodeficiency virus infection
31. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons
32. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus
33. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
34. A packaging cell line for lentiviral vectors
35. Lentiviral vectors: Regulated gene expression
36. A stable system for the high-titer production of multiply attenuated lentiviral vectors
37. Cellular delivery of trophic factors for the treatment of Huntington's disease: Is neuroprotection possible?
38. Lentiviral gene transfer to the nonhuman primate brain
39. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
40. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation
41. Retinal degeneration is rescued in transgenic rd mice by expression of the cGMP phosphodiesterase beta subunit
42. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells
43. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
44. A block to human immunodeficiency virus type 1 assembly in murine cells
45. Gene therapy and pharmacological treatment of inherited neurological disorders
46. Stable gene transfer to the nervous system using a non-primate lentiviral vector
47. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector
48. Development of a self-inactivating lentivirus vector
49. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells
50. Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system
51. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
52. Efficient transfer, integration, and sutained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
53. Lentiviruses as gene transfer agents for delivery to non-dividing cells
54. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells
55. Fetal nigral transplantation as a therapy for Parkinson's disease
56. Efficient lentiviral transduction of liver requires cell cycling in vivo
57. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease
58. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
59. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors
60. Behavioral abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
61. Development of multigene and regulated lentivirus vectors
62. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle
63. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin
64. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
65. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus
66. Of neurons and gene chips
67. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells
68. Lentiviral vectors pseudotyped with envelope glycoproteins derived from gibbon ape leukemia virus and murine leukemia virus 10A1
69. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer
70. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome
71. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy
72. Gene therapy-promises, problems and prospects
73. Huntington disease
74. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector
75. Development of a novel trans-lentiviral vector that affords predictable safety
76. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
77. HIV-1 genome nuclear import is mediated by a central DNA flap
78. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
79. Self-inactivating lentiviral vector for safe and efficient in vivo gene delivery
80. Woodschuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors